Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anbenitamab (KN026) plus Chemotherapy in HER2+ Gastric Cancer
NCT05427383Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Gastric cancer (HER2-positive) and gastroesophageal junction adenocarcinoma comparing KN026 + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Progression Free Survival up to 2.5 years and Overall Survival up to 2.5 years. Started Apr 2022; status: recruiting.
02
Drugs
anbenitamab
03
Conditions
Gastric cancer (HER2-positive)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05427383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427383.